MX2020003314A - Expansion y uso de fracciones de celulas nk ampliadas. - Google Patents

Expansion y uso de fracciones de celulas nk ampliadas.

Info

Publication number
MX2020003314A
MX2020003314A MX2020003314A MX2020003314A MX2020003314A MX 2020003314 A MX2020003314 A MX 2020003314A MX 2020003314 A MX2020003314 A MX 2020003314A MX 2020003314 A MX2020003314 A MX 2020003314A MX 2020003314 A MX2020003314 A MX 2020003314A
Authority
MX
Mexico
Prior art keywords
expanded
expansion
cell fractions
cell
methods
Prior art date
Application number
MX2020003314A
Other languages
English (en)
Inventor
Tony Peled
Original Assignee
Gamida Cell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gamida Cell Ltd filed Critical Gamida Cell Ltd
Publication of MX2020003314A publication Critical patent/MX2020003314A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Son proporcionados métodos para expandir una fracción de células asesinas naturales (NK) para el trasplante en un sujeto y particularmente, métodos para proporcionar fracciones de células NK trasplantables y protocolos para su uso, que pueden ser empleadas para aplicaciones en trasplantes de células e infusiones para el tratamiento del cáncer y otra enfermedad.
MX2020003314A 2017-10-02 2018-09-27 Expansion y uso de fracciones de celulas nk ampliadas. MX2020003314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762566554P 2017-10-02 2017-10-02
PCT/IB2018/057475 WO2019069184A2 (en) 2017-10-02 2018-09-27 EXPANSION AND USE OF EXTENDED NK CELL FRACTIONS

Publications (1)

Publication Number Publication Date
MX2020003314A true MX2020003314A (es) 2020-10-28

Family

ID=65957112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003314A MX2020003314A (es) 2017-10-02 2018-09-27 Expansion y uso de fracciones de celulas nk ampliadas.

Country Status (12)

Country Link
US (2) US11834677B2 (es)
EP (1) EP3691660A4 (es)
JP (1) JP7239567B2 (es)
CN (1) CN109593711A (es)
AU (1) AU2018346818A1 (es)
BR (1) BR112020006391A2 (es)
CA (1) CA3076456A1 (es)
CL (1) CL2020000734A1 (es)
IL (1) IL273757A (es)
MX (1) MX2020003314A (es)
SG (1) SG11202002597YA (es)
WO (1) WO2019069184A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020006391A2 (pt) * 2017-10-02 2020-09-24 Gamida-Cell Ltd. método para preparar uma fração de células nk transplantáveis para transplante em um indivíduo e para tratar uma doença hematológica em um indivíduo humano, e, fração de células nk transplantáveis e de células nk humanas transplantáveis.
US20220249555A1 (en) * 2019-03-21 2022-08-11 Gamida Cell Ltd. Expanded nk cell fractions for transplantation in combination therapy
WO2023003809A1 (en) * 2021-07-18 2023-01-26 Gamida-Cell Ltd. Therapeutic nk cell populations
CA3228566A1 (en) * 2021-08-10 2023-02-16 Yona Geffen Anti-her2 car nk cells, methods of their production and uses thereof
CN117721079A (zh) * 2024-01-26 2024-03-19 广东壹加再生医学研究院有限公司 一种促进nk细胞抗肿瘤活性的培养基及培养方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US20130131573A1 (en) * 2009-08-18 2013-05-23 William H. Hildebrand Selective anti-hla antibody removal device and methods of production and use thereof
US20130058921A1 (en) 2009-10-30 2013-03-07 Frits VAN RHEE Use of autologous effector cells and antibodies for treatment of multiple myeloma
ES2851601T3 (es) * 2009-12-29 2021-09-08 Gamida Cell Ltd Métodos para mejorar la proliferación y actividad de los linfocitos citolíticos naturales
WO2012009422A1 (en) 2010-07-13 2012-01-19 Anthrogenesis Corporation Methods of generating natural killer cells
CN104321425B (zh) 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
MX2015001871A (es) 2012-08-13 2015-09-21 Anthrogenesis Corp Celulas asesinas naturales y usos de las mismas.
US11471486B2 (en) 2012-09-04 2022-10-18 Inven2 As Selective and controlled expansion of educated NK cells
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US20180021378A1 (en) 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
WO2016122014A1 (ko) 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
KR20230147769A (ko) * 2015-05-28 2023-10-23 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
US20200016198A1 (en) 2015-11-05 2020-01-16 Glycostem Therapeutics B.V. Composition for use in immunotherapy
BR112020006391A2 (pt) 2017-10-02 2020-09-24 Gamida-Cell Ltd. método para preparar uma fração de células nk transplantáveis para transplante em um indivíduo e para tratar uma doença hematológica em um indivíduo humano, e, fração de células nk transplantáveis e de células nk humanas transplantáveis.

Also Published As

Publication number Publication date
JP7239567B2 (ja) 2023-03-14
AU2018346818A1 (en) 2020-05-14
CN109593711A (zh) 2019-04-09
WO2019069184A2 (en) 2019-04-11
US20200263134A1 (en) 2020-08-20
WO2019069184A3 (en) 2019-07-25
EP3691660A4 (en) 2021-07-07
CA3076456A1 (en) 2019-04-11
SG11202002597YA (en) 2020-04-29
JP2020535816A (ja) 2020-12-10
US11834677B2 (en) 2023-12-05
EP3691660A2 (en) 2020-08-12
CL2020000734A1 (es) 2020-09-11
IL273757A (en) 2020-05-31
US20240101960A1 (en) 2024-03-28
BR112020006391A2 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2020003314A (es) Expansion y uso de fracciones de celulas nk ampliadas.
MX2020006688A (es) Celulas presentadoras de antigenos artificiales y metodos de uso.
PH12017500803A1 (en) Anti-pd-1 antibodies
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
MX2017013002A (es) Composicion y kits para matrices pseudoplasticas de microgel.
MX2022008085A (es) Moleculas peque?as contra cereblon para mejorar la funcion efectora de los linfocitos t.
TWD170353S (zh) 項鍊
CN106661570A8 (zh) 通过与氨甲蝶呤选择偶联的睡美人转座子制备工程化t细胞
SG10201810723VA (en) Improved t cell compositions
EP3441460A4 (en) EX-VIVO EXPANSION PROCEDURE FOR NUCLEAR CELL NUCLEAR BLOODS AND KIT, AND USE THEREOF
MX2017005344A (es) Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
MX2016010293A (es) Micro-organoides, y metodos de fabricacion y usos los mismos.
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
EA201691826A1 (ru) Способ использования графена и других двухмерных материалов in vivo и in vitro
MX2017006685A (es) Tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas usando terapias reductoras de amoniaco.
MX2017009720A (es) Composiciones de oligosacaridos para el uso en composiciones nutricionales y metodos para producirlas.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
MX2016013426A (es) Expansores de tejido con hidrogel novedosos.
AU2018337668A1 (en) Improved supraparticles
JP2019524211A5 (es)
EP3181686A4 (en) Culture medium and method for enriching and maintaining cancer stem cells (cscs) using said medium
ZA201605549B (en) Fgf-18 in graft transplantation and tissue engineering procedures
SG10201803094QA (en) Monoliths with attached recognition compounds, arrays thereof and uses thereof